[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil). Of these 46 patients, 23 treated by CMxMF regimen gave a response rate of 87% (20/23) and 23 treated by CAMF regimen gave a response rate of 82.6% (19/23) (P > 0.05). Following up to the end of June, 1992, 21 patients in CMxMF regimen were still alive with a median survival of 16 (6-24) months and 20 patients in CAMF regimen with a median survival of 12 (3-24) months. The side effects were tolerable in both groups. The authors consider that mitoxantrone is as effective as adriamycin in the treatment of advanced breast cancer.